Ionix Pharmaceuticals Patents Granted On Novel Analgesic Program: Series C Financing Initiated
10/19/2005 5:08:47 PM
Ionix Pharmaceuticals, a leader in the discovery and development of analgesic drugs, today announced that it has been granted further patent protection in support of its programmes to develop analgesics that modulate the sodium channel drug target, Nav1.8. On May 26, Ionix was granted two patents which cover proteins that regulate the expression of this target. These inventions form the basis of the company's IX-4000 drug discovery programme for the treatment of chronic pain and urological disorders.
comments powered by